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ORIGINAL ARTICLE
On Modelling Minimal Disease Activity
CHRISTOPHER H. JACKSON,1 LI SU,1 DAFNA D. GLADMAN,2 AND VERNON T. FAREWELL1
Objective. To explore methods for statistical modelling of minimal disease activity (MDA) based on data from inter-
mittent clinic visits.
Methods. The analysis was based on a 2-state model. Comparisons were made between analyses based on “complete
case” data from visits at which MDA status was known, and the use of hidden model methodology that incorporated
information from visits at which only some MDA defining criteria could be established. Analyses were based on an
observational psoriatic arthritis cohort.
Results. With data from 856 patients and 7,024 clinic visits, analysis was based on virtually all visits, although only
62.6% provided enough information to determine MDA status. Estimated mean times for an episode of MDA varied
from 4.18 years to 3.10 years, with smaller estimates derived from the hidden 2-state model analysis. Over a 10-year
period, the estimated expected times spent in MDA episodes of longer than 1 year was 3.90 to 4.22, and the probabili-
ty of having such an MDA episode was estimated to be 0.85 to 0.91, with longer times and greater probabilities seen
with the hidden 2-state model analysis.
Conclusion. A 2-state model provides a useful framework for the analysis of MDA. Use of data from visits at which
MDA status can not be determined provide more precision, and notable differences are seen in estimated quantities
related to MDA episodes based on complete case and hidden 2-state model analyses. The possibility of bias, as well as
loss of precision, should be recognized when complete case analyses are used.
INTRODUCTION
There is currently considerable interest in the concept of
minimal disease activity (MDA) for rheumatic diseases.
The Outcome Measures in Rheumatology Clinical Trials 6
Conference agreed on a conceptual definition of MDA as
“that state of disease activity deemed a useful target of
treatment by both the patient and physician, given current
treatment possibilities and limitations.”
Coates et al (1) examined a specific definition of MDA
for psoriatic arthritis (PsA) originally suggested in Coates
et al (2). They compared patients who achieved sustained
MDA, defined as satisfying the definition for a minimum
of 12 months, to those not achieving this goal. In addition,
they examined models for the time to first achievement of
sustained MDA. There are challenges to the analysis of
events defined by prolonged observation of a condition (3)
as is necessary for the analysis of sustained MDA; patients
may go in and out of an MDA state, and the time with
MDA may be of interest. In this study we explore the use
of a 2-state model for the presence and absence of MDA in
PsA. We also illustrate how the model may be used to
quantify aspects of sustained MDA. Estimation of the
model is based on clinical cohort data with patients being
observed at intermittent time points, i.e., clinic visits. Esti-
mation of the 2-state model that incorporates visits with
partial information on MDA status may be an improve-
ment on estimation of the model based on visits with com-
plete information only.
PATIENTS AND METHODS
Our data consist of 7,024 clinical visits from 856 patients
seen at the University of Toronto PsA Clinic since 2003.
Patients were evaluated using a standard protocol every 6
to 12 months. Clinical assessments included a 68-joint
tender joint count (TJC), a 66-joint swollen joint count
(SJC), the Spondylarthritis Research Consortium of Canada
enthesitis instrument (since 2008, and examination of
Achilles tendons and plantar fascia insertions previously),
and dactylitis measures using the Leeds Dactylitis instru-
ment (4,5). Skin assessment included both the body sur-
face area (BSA) and the Psoriasis Area and Severity Index
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(PASI) (6). A clinically damaged joint count was recorded
in addition to the TJC and SJC at each visit. Damaged joints
were defined as those that had a reduced range of motion
.20% of the range that could not be explained by joint
effusion, joints that had undergone surgery, or joints show-
ing deformity, subluxation, loosening, or ankylosis. The
reliability of this measure has been demonstrated in the
Toronto clinic and across Canada (7,8). A physician global
assessment was completed, and patients completed self-
reported questionnaires, including the Health Assessment
Questionnaire (HAQ) and patient global assessments rou-
tinely. The criteria for the definition of MDA used by
Coates et al (1) were $5 of the following 7 criteria: 1) TJC
#1, 2) SJC #1, 3) PASI score #1 or BSA #3%, 4) patient
pain visual analog score #15 mm, 5) patient global disease
activity visual analog score #20 mm, 6) HAQ score #0.5,
and 7) entheseal points#1.
The underlying basis of our proposed analyses is the 2-
state model illustrated in Figure 1. The model is based on
the assumptions that a patient either has or does not have
MDA and that, although patients are observed intermittent-
ly at clinic visits, a patient may change “state” at any point
in time. Some MDA episodes may be sustained for 12
months or more, and some may be transient, lasting less
than 12 months; these can be distinguished when simulat-
ing from the model. The parameters to be estimated from
this model are the 2 rates of transition: r1 from no MDA to
MDA and r2 from MDA to no MDA. Maximum likelihood
estimation of the rates is used. If i and j are used to repre-
sent model states, where i and j take on values 1 or 2
depending on whether they represent the no MDA or MDA
state, the maximum likelihood estimation only requires the
specification of expressions for the probability of observing
a patient in state i at one visit where MDA status can be
determined and state j at the next visit where MDA status
can be determined. This approach allows taking account of
the intermittent observation of the patients and the length
of time between any 2 clinic visits. For simplicity, r1 and r2
are taken to be constant over followup time, although this
restriction can be relaxed.
From any particular clinic visit, information may be
available on all, none, or a subset of the 7 binary criteria
used to define MDA. Typically, estimation of the 2-state
model in Figure 1 would be based only on visits where
either at least 5 of 7 criteria were observed and satisfied or
at least 3 of 7 criteria were observed and not satisfied so
that MDA/no MDA status can be determined. This is
termed a complete case analysis. Two problems may arise
with this approach. The first is that for some visits there
may be information on some of the 7 MDA criteria, and if
this information can be used to give some information on
the likely MDA state at those visits then estimation of
model parameters may be more precise. The second is that
when only certain variables are available, this may, in
some way, be informative about the likely MDA status. If
this is the case, then basing information only on visits
with a known MDA status may lead to biased estimation.
One approach to dealing with these 2 problems is to
regard the 2-state MDA model as a partially hidden multi-
state model. This means that while for some clinic visits
we know MDA status, for others it is unknown or
“hidden.” To fit a hidden Markov model, we need to
define statistical models for the distributions of the 7
MDA defining criteria conditional on having MDA and
conditional on not having MDA. Let X1, X2, . . . X7 repre-
sent the 7 binary variables that are needed to specify the 7
MDA criteria. In the definition of MDA, these are all bina-
ry indicators taking on values of 0 or 1, depending on
whether a certain condition is satisfied. Models for these
binary indicators will specify the distribution of each Xi
conditional on MDA, f(Xi | MDA) and conditional on no
MDA, f(Xi | no MDA), as Bernoulli random variables. The
assumption is made that these variables are independent-
ly distributed, after conditioning on MDA status. Clearly
without this conditioning on active disease status the
independence assumption would be unreasonable, but we
feel it is less problematic given the conditioning, although
it is not likely to be exactly true.
While MDA is defined using binary indicators, an alter-
native approach to fitting the hidden multistate model is
to directly model each of the variables used to define the
criteria. This will require modelling 8 quantitative varia-
bles, as either PASI or BSA can be considered for the third
criterion. For a clinic visit where MDA status is unknown,
let xall represent either the subset of the 7 binary indica-
tors or the subset of the 8 variables used to define the bina-
ry indicators that are observed. Then instead of just the
probability of being in the MDA or no MDA states being
used for maximum likelihood estimation, the joint proba-
bility of being in a state and having the observed xall
becomes the basis of the likelihood estimation. When the
state is unknown for a patient, the probability used for
that clinic visit for estimation is just the probability func-
tion for the observed xall, f(xall)5 f(xall | MDA) Prob
(MDA)1 f(xall | no MDA) Prob (no MDA). Prob (MDA)
and Prob (no MDA) are calculated based on the multistate
process for moving between the underlying states. The
rates of moving between these states, and the probabilities
of the binary outcome variables conditionally on the MDA
states, can be examined simultaneously by maximum
likelihood estimation.
Figure 1. A 2-state model for minimal disease activity (MDA).
Significance & Innovations
 The use of a “hidden” 2-state model provides a
useful framework for analysis of data on minimal
disease activity (MDA).
 Inclusion of data from clinic visits at which only
partial information is available regarding MDA sta-
tus leads to increased precision of estimation and
protection against bias.
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When modelling the 8 quantitative variables, the inte-
ger patient pain and patient global activity scores are
modelled as binomial variables taking integer values from
0 to 10, and the remaining 6 variables, which also take
integer values (after multiplying HAQ and PASI by 100),
are modelled as negative binomial variables. Alternative
modelling could be considered, but these are adopted as
convenient and reasonable approximations.
Based on estimation of the 2 rates, r1 and r2, it is also
possible to estimate the expected time spent in the MDA
state over any fixed time period, the average (mean) time
that a patient remains in the MDA and no MDA states
(mean sojourn time), and the probability of MDA occur-
ring during a fixed time period, given the patient is not in
the MDA state at the start of the time period. Furthermore,
it is also possible to examine, via numerical evaluation or
via simulation, comparable related measures associated
with sustained MDA of at least 1 year’s duration.
It is also possible to estimate the parameters of the hid-
den multistate model in Figure 1 using only the additional
information from a single X variable. While not recom-
mended in practice, this will also be done for illustrative
purposes. Estimation for the various multistate models
was done with the msm package (version 1.5.2) (9) in the
statistical computing environment R (10).
RESULTS
Only 62.6% of 7,024 clinic visits had sufficient data to
determine MDA status. However, all but 8 of these visits
provided information on at least 1 of the MDA criteria. For
example, the joint counts and enthesitis information were
all recorded in approximately 95% of the visits. The num-
ber of visits with none, 1, 2, 3, 4, 5, 6, and 7 binary varia-
bles missing were 1,367, 2,807, 1,449, 924, 357, 96, 16,
and 8, respectively. The pattern of missing data is dis-
played in Figure 2.
In our data set, 619 patients had more than 1 observa-
tion of confirmed MDA or no MDA. For all pairs of visits
for which MDA status at both visits could be determined,
there were 1,390 pairs where the patient did not have
Figure 2. Pattern of missingness in binary indicators. TJC5 total joint count; SJC5 swollen joint
count; PASI5Psoriasis Area and Severity Index; PTPAINV5patient pain visual analog score;
HAQ5Health Assessment Questionnaire; ENTH TOT5 entheseal points; PTPSA5patient global
activity visual analog score.
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MDA at both visits, 825 where MDA was recorded at both
visits, 195 where the patients moved from no MDA to
MDA, and 144 with movement from MDA to no MDA.
These visits are the basis of a complete case analysis.
Table 1 presents the percentage of visits for which infor-
mation on each of the MDA criteria are missing. The
patient global disease activity score is missing approxi-
mately 50% of the time, as is the HAQ score, which is
only administered once a year. The psoriasis measures
and the patient pain score are missing at 16% and 17% of
clinic visits, respectively. The remaining criteria are miss-
ing less than 10% of the time. In addition, Table 1
presents the percentage of visits at which each criterion
was satisfied for both known MDA and known no MDA
visits. For example, the patient pain score is hardly ever
positive unless MDA is observed, whereas the entheseal
points criterion is positive most of the time whatever the
MDA status. Therefore, we might expect the patient pain
score to be better at discriminating MDA status than
entheseal points. The HAQ criterion is satisfied 95% of
the time if MDA is observed and only 25% of the time if
not. The comparable numbers for the patient global dis-
ease activity score criterion are 85% and 5%. The TJC and
SJC criteria are satisfied more than 95% of the time when
MDA is observed, but are also positive 35% and 52% of
the time that MDA is not observed. The psoriasis criterion
is positive 76% and 35% of the time when MDA and no
MDA, respectively, are observed. Supplementary Figure 1
(available on the Arthritis Care & Research web site
at http://onlinelibrary.wiley.com/doi/10.1002/acr.22687/
abstract) shows histograms of the 8 quantitative variables
used to define MDA status along with the thresholds used
in the MDA definition.
Also shown in Table 1 are the estimated probabilities of
a positive criterion based on the various hidden multistate
models. These are broadly consistent with the observed
values from the complete case visits, and the differences
observed could arise from model misspecification or from
an informative observation pattern linked to only using
complete case visits and resulting in biased estimation
from the complete case analysis.
Table 2 presents the estimated mean time to stay in the
MDA and no MDA states, the estimated expected time
that a patient starting in the no MDA state will be in the 2
states, and the expected number of episodes in the 2 states
over a 10-year period, as well as the probability of MDA
occurring during those 10 years. The latter 3 quantities are
also estimated for sustained MDA and, where appropriate,
for a transient MDA episode less than 1 year in duration.
Results are provided for the complete case, the multivari-
ate binary hidden multistate model, and the multivariate
quantitative hidden multistate model, and 95% confi-
dence intervals (95% CIs) are displayed.
The mean times to stay in a state are smaller from both
hidden multistate models than from the complete case ana-
lysis, and the quantitative-based results are smaller than
the binary-based results. These differences may be related
to the fact that the hidden multistate model estimation is
based on more frequent observations, and short-term fluc-
tuations may be suggesting more state changes. There are
less dramatic differences in the estimated expected total
time, more than 10 years, in the 2 states from the various
models, as well as in the expected total time in a sustained
MDA state. The expected total time in the first and subse-
quent years of an MDA episode are also given.
The expected number of episodes in no MDA, MDA,
sustained MDA, and transient MDA are also higher when
a hidden multistate model is used and it can be seen that
more than 2 MDA episodes are not expected over a 10-
year period. The probability of achieving MDA and the
probability of sustained MDA at least once in a 10-year
period are similarly estimated to be higher from the hid-
Table 1. Percentage of visits where binary MDA criteria are satisfied, observed, and estimated, and percentage of visits with
missing information*
TJC SJC PASI1 BSA PTPAINV PTPSA HAQ ENTH TOT
Missing 4 5 16 17 52 50 6
Complete cases
Criteria satisfied 67 75 49 28 41 58 94
Satisfied and no MDA 35 52 35 2 5 25 87
Satisfied and MDA 97 96 76 72 85 95 99
Univariate binary model estimates
Satisfied and no MDA 44 60 35 2 6 27 90
Satisfied and MDA 97 96 72 66 82 96 99
Multivariate binary model estimates
Satisfied and no MDA 46 62 41 3 6 30 90
Satisfied and MDA 95 94 61 60 79 94 99
Univariate quantitative model estimates
Satisfied and no MDA 46 63 25 1 2 36 92
Satisfied and MDA 95 95 52 57 76 93 99
Multivariate quantitative model estimates
Satisfied and no MDA 47 63 32 1 2 38 92
Satisfied and MDA 92 93 43 54 75 92 99
* Values are the percentage. MDA5minimal disease activity; TJC5 total joint count; SJC5 swollen joint count; PASI5Psoriasis Area and Severity
Index; BSA5body surface area; PTPAINV5patient pain visual analog score; PTPSA5patient global activity visual analog score; HAQ5Health
Assessment Questionnaire; ENTH TOT5 entheseal points.
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den multistate models, with the highest coming from the
multivariate quantitative results. The estimated probabili-
ties of achieving MDA all exceed 90%, while for sustained
MDA the estimates vary from 85% with the complete case
analysis to 91% with the multivariate quantitative multi-
state analysis. It can be seen that there is no overlap
between the CIs for both probabilities from the complete
case and multivariate quantitative multistate analyses.
Table 2 also illustrates that the estimates from the quan-
titative and the binary hidden multistate models are more
precise (smaller CIs) than the complete case analysis. The
SEs from these 3 models for the mean times in the states
are 0.17, 0.24, and 0.29, respectively. This is consistent
with the greater amount of data used to estimate the hid-
den multistate models.
For illustration purposes, Figure 3 presents the estimat-
ed mean sojourn times for the various univariate hidden
multistate models and compares them with those arising
from the complete case and the 2 multivariate hidden
multistate model analyses. For both the TJC and the SJC,
slightly shorter mean sojourn times come from the binary
variable model in contrast to the results for other univari-
ate models and the multivariate models that have longer
times from the binary models. However, the most marked
difference arises with the univariate HAQ-based models,
which give much longer sojourn times than the other mod-
els. This may arise because there is less fluctuation
between HAQ observations (which are only taken once
per year) than for the other variables (potentially mea-
sured at each visit). Fluctuations will, in a general sense,
tend to imply more state changes and this may account for
the extreme results based on HAQ only.
DISCUSSION
Adopting the framework of multistate models, we have
shown that investigations of MDA in PsA, which is
Table 2. Estimates and 95% confidence intervals for quantities from 3 methods of estimating a 2-state
model for MDA*
Complete case Multivariate binary Multivariate quantitative
Mean sojourn time in. . .
No MDA 4.06 (3.63–4.53) 3.43 (3.09–3.81) 2.82 (2.56–3.10)
MDA 4.18 (3.65–4.79) 3.82 (3.37–4.33) 3.10 (2.78–3.45)
Expected time over 10 years in. . .
No MDA 5.95 (5.69–6.25) 5.69 (5.43–5.95) 5.53 (5.30–5.78)
MDA 4.05 (3.75–4.31) 4.31 (4.05–4.57) 4.47 (4.22–4.70)
MDA episodes lasting ,1 year 0.15 (0.12–0.17) 0.18 (0.15–0.21) 0.25 (0.21–0.29)
MDA episodes lasting $1 year† 3.90 (3.59–4.16) 4.13 (3.88–4.40) 4.22 (3.96–4.45)
First year of MDA 1.26 (1.16–1.34) 1.39 (1.30–1.49) 1.61 (1.52–1.72)
Later years of MDA 2.79 (2.53–3.02) 2.92 (2.70–3.15) 2.86 (2.63–3.07)
Expected number of episodes in. . .
No MDA 1.97 (1.85–2.09) 2.13 (2.00–2.26) 2.44 (2.30–2.60)
MDA 1.47 (1.35–1.59) 1.65 (1.53–1.79) 1.96 (1.84–2.12)
MDA lasting ,1 year 0.31 (0.26–0.38) 0.38 (0.32–0.45) 0.54 (0.46–0.64)
MDA lasting $1 year 1.16 (1.08–1.23) 1.27 (1.20–1.35) 1.42 (1.36–1.50)
Probability of visiting at least once
MDA 0.92 (0.89–0.94) 0.94 (0.93–0.96) 0.97 (0.96–0.98)
MDA lasting $1 year 0.85 (0.82–0.87) 0.88 (0.86–0.91) 0.91 (0.90–0.93)
* Values are the estimate (95% confidence interval). MDA5minimal disease activity.
† Episodes starting between 9–10 years that eventually lasted $1 years are counted as “lasting $1 year” for this categoriza-
tion, but the time spent in them is truncated at the 10-year point.
Figure 3. Mean sojourn times with no minimal disease activity
(MDA) and MDA, estimated from the hidden multistate and multi-
state models. ENTH TOT5 entheseal points; HAQ5Health Assess-
ment Questionnaire; PTPSA5patient global activity visual analog
score; PTPAINV5patient pain visual analog score; BSA5 body sur-
face area; PASI5Psoriasis Area and Severity Index; SJC5 swollen
joint count; TJC5 total joint count; IQR5 interquartile range.
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defined as a composite outcome based on 7 binary criteria,
can make use of data from clinic visits at which MDA sta-
tus can not be determined due to missing data related to
these 7 criteria. We have shown that this can provide
more precise information but also notable differences in
estimates of quantities related to the length of MDA epi-
sodes, the cumulative time spent with MDA, and the prob-
ability of MDA over a defined time period. Comparable
differences are also seen when sustained MDA is exam-
ined. The reasons for these differences cannot be unam-
biguously determined but the possibility of bias, as well
as loss of precision, from only using visits at which MDA
status is known must be considered. In light of this, con-
clusions regarding MDA based on complete case analyses
should be treated with caution.
Coates et al (1) previously examined MDA in PsA, but
as well as requiring 5 of the 7 criteria to be fulfilled, it was
also required that MDA must be observed at consecutive
visits for a minimum of 12 months in order to focus on
sustained MDA. In our current data set, which updates
that of Coates et al and is based on complete case data, 229
of 619 patients (37%) achieved this, and the median dura-
tion of such episodes was 42 months (3.5 years), which is
greater than the median of 28 months presented by Coates
et al based on earlier data on 344 patients. While there
may be other reasons for this difference, the difference is
at least partially explained simply on the basis of followup
times, as the length of MDA episodes will be censored at
the last observation time. For these episodes in our data,
which begin prior to 2008 and is the cut off for the data of
Coates et al, the mean duration is 76 months (6.3 years),
reflecting the additional followup of the patients consid-
ered by Coates et al. For MDA episodes in our data begin-
ning after 2007, the mean duration is 27 months (2.3
years). Therefore, estimation of the length of MDA epi-
sodes in this manner is problematic and the estimated
mean durations arising from a 2-state model should be
preferred as these are valid estimates not influenced by
followup times.
Our 2-state model can also be extended to allow the
transition rates to depend on calendar time and therefore
to address specifically whether MDA has been seen more
frequently in recent years. In doing so, we estimate, using
our quantitative hidden multistate model, that the rate of
transition to MDA is estimated to be increased by a factor
of 1.2 (95% CI 1.0–1.5) in the years 2007–2009 and by a
factor of 1.3 (95% CI 1.1–1.7) in the years 20101, com-
pared with the period prior to 2007. There is also some
suggestive evidence that the rate of transition back to no
MDA may have also increased. From the same model, the
rate of transition out of MDA is estimated to be increased
by factors of 1.3 (95% CI 1.0–1.7) and 1.1 (95% CI 0.9–1.5)
for the periods 2007–2009 and 20101, respectively.
As was done to examine this dependence of transition
rates on calendar time, it is relatively straightforward to
generalize the multistate model to allow the transition
rates to depend on other explanatory variables so that pre-
dictors of MDA can be investigated. However, our aim in
this study has been to highlight some potentially impor-
tant issues in the use and modelling of MDA data.
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